Long Survival Confirmed in CML Patients Who Respond to Interferon

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

ORLANDO-Patients with chronic myelogenous leukemia (CML) who have a complete cytogenetic response (CCgR) to interferon-alfa have a long survival, and low-risk patients have a projected 10-year survival of more than 80%, Francesca

ORLANDO—Patients with chronic myelogenous leukemia (CML) who have a complete cytogenetic response (CCgR) to interferon-alfa have a long survival, and low-risk patients have a projected 10-year survival of more than 80%, Francesca Bonifazi, MD, reported at the 43rd Annual Meeting of the American Society of Hematology (ASH abstract 1466).

Dr. Bonafazi, of Bologna University, Italy, presented data compiled in nine European countries by the European Study Group on Interferon-alfa in CML.

This study included 317 patients with Philadelphia chromosome-positive CML who had a CCgR after treatment with interferon-alfa alone. The median time to complete hematologic response was 2 to 7 months in the patients as a whole, and the median time to first CCgR was 19 months (range, 3 to 84 months).

At last contact, 212 patients (68%) were still in first continuous CCgR. The remaining 105 patients had lost CCgR, but 53% were still alive and in chronic phase. Ten-year survival from first CCgR was 72% for the group as a whole and was much higher for low-risk patients (89% for Sokal’s low risk and 81% for the IFN score low risk), Dr. Bonifazi said.

Interferon-alfa was discontinued in 23 patients for response loss, in 36 for chronic toxicity, and in 8 because they were in stable CCgR for more than 5 years. Dr. Bonifazi reported that 15 of the 36 cases discontinued for toxicity and 7 of the 8 discontinued after response of more than 5 years were still in unmaintained CCgR for 2 to 5 years after discontinuation of treatment.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content